Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $29.00

Intellia Therapeutics (NASDAQ:NTLA) had its target price boosted by investment analysts at Leerink Partners from $27.00 to $29.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Leerink Partners’ price target points to a potential upside of 110.22% from the stock’s current price.

Several other research firms have also issued reports on NTLA. Royal Bank Of Canada increased their target price on shares of Intellia Therapeutics from $9.00 to $15.00 and gave the stock a “sector perform” rating in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, January 22nd. Chardan Capital restated a “buy” rating and set a $26.00 price objective on shares of Intellia Therapeutics in a research report on Friday. Wall Street Zen cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, January 18th. Finally, KeyCorp set a $25.00 price target on Intellia Therapeutics in a research note on Wednesday, January 28th. Nine investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Intellia Therapeutics has a consensus rating of “Hold” and a consensus target price of $19.43.

Intellia Therapeutics Trading Down 10.7%

Intellia Therapeutics stock traded down $1.65 during trading on Tuesday, reaching $13.80. The company had a trading volume of 3,372,937 shares, compared to its average volume of 5,340,344. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -3.60 and a beta of 2.09. The firm’s 50-day simple moving average is $12.01 and its 200 day simple moving average is $13.08. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.16. The business had revenue of $23.02 million during the quarter, compared to analyst estimates of $12.17 million. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.Intellia Therapeutics’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.27) earnings per share. On average, analysts predict that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Buying and Selling at Intellia Therapeutics

In other news, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the transaction, the executive vice president owned 98,533 shares in the company, valued at $907,488.93. This trade represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO John M. Leonard sold 34,146 shares of Intellia Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the sale, the chief executive officer directly owned 1,013,339 shares in the company, valued at $9,332,852.19. This trade represents a 3.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 53,051 shares of company stock valued at $488,600 in the last 90 days. Insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in Intellia Therapeutics in the fourth quarter worth about $245,000. Invesco Ltd. boosted its holdings in Intellia Therapeutics by 5.8% during the 4th quarter. Invesco Ltd. now owns 433,290 shares of the company’s stock valued at $3,895,000 after acquiring an additional 23,870 shares during the period. Axxcess Wealth Management LLC grew its position in Intellia Therapeutics by 20.1% in the 4th quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company’s stock valued at $192,000 after acquiring an additional 3,583 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in Intellia Therapeutics in the fourth quarter worth $90,000. Finally, XTX Topco Ltd bought a new stake in shares of Intellia Therapeutics during the fourth quarter worth $402,000. 88.77% of the stock is currently owned by institutional investors.

Trending Headlines about Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical hold on the MAGNITUDE Phase 3 IND for nexiguran ziclumeran (nex‑z) in transthyretin amyloidosis with cardiomyopathy (ATTR‑CM) — removes a major regulatory overhang and permits the late‑stage trial to proceed, which is the primary near‑term clinical catalyst for the stock. Read More.
• Positive Sentiment: Market reacted to the FDA action with a price uptick (reports noted a ~4.8% intraday rise), signaling investor relief and renewed focus on trial execution and timelines. Read More.
• Positive Sentiment: Multiple analyst upgrades/target raises — HC Wainwright raised its target to $30 (buy), Citizens JMP to $28 (market outperform), William Blair upgraded to outperform, and other firms reiterated buy ratings. These broker actions increase attention and imply significant upside vs. current levels. Read More. and Read More.
• Neutral Sentiment: Intellia presented four posters at AAAAI including three‑year follow‑up data from a one‑time 50 mg dose of lonvoguran ziclumeran (lonvo‑z) and patient‑survey findings on treatment burden/unmet needs in hereditary angioedema (HAE). Longer‑term durability data can be positive if confirmed, while patient‑burden findings underscore market opportunity and remaining unmet needs. Read More.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.